AdultPediatricGeriatricDosage Forms & Strengths oral inhalation aerosol 40mcg/actuation 80mcg/actuation Available as a breath-actuated inhaler (Qvar RediHaler) Note: Qvar RediHaler replaced the Qvar metered-dose inhaler February 2018 Chronic Asthma Indicated for maintenance treatment of asthma as prophylactic therapy No prior history of inhaled corticosteroid use: 40-80 mcg inhaled PO q12hr initially; may increase dose if needed; not to exceed 320 mcg BID Prior history of inhaled corticosteroid use: 40-160 mcg inhaled PO q12hr based on previous inhaled corticosteroid product and disease severity; not to exceed 320 mcg BID See Administration Dosing Considerations Improvement in pulmonary function is usually apparent within 1-4 weeks after initiation of treatment Limitations of use: Not indicated for relief of acute bronchospasmDosage Forms & Strengths oral inhalation aerosol 40mcg/actuation 80mcg/actuation Available as a breath-actuated inhaler (Qvar RediHaler) Note: Qvar RediHaler replaced the Qvar metered-dose inhaler February 2018 Chronic Asthma Indicated for maintenance treatment of asthma as prophylactic therapy <4 years: Safety and efficacy not established 4-11 years: 40 mcg inhaled PO BID for patients with/without prior history of inhaled corticosteroid use; may increase dose for adequate response after ≥2 weeks therapy; not to exceed 80 mcg inhaled BID ≥12 years No prior history of inhaled corticosteroid use: 40-80 mcg inhaled PO q12hr initially; may increase dose for adequate response after ≥2 weeks therapy; not to exceed 320 mcg BID Prior history of inhaled corticosteroid use: 40-160 mcg inhaled PO q12hr based on previous corticosteroid inhaled product and disease severity; may increase dose for adequate response after ≥2 weeks therapy; not to exceed 320 mcg BID Dosing Considerations May cause growth velocity reduction with extended use; monitor closely if on prolonged therapy; advise downward dose titration over time to the lowest level that maintains proper asthma control Limitations of use: Not indicated for relief of acute bronchospasmStart at lower end of dosing range due to increased risk of adverse effectsInteraction CheckerEnter a drug name and beclomethasone, inhaledNo Results No Interactions Found Interactions FoundContraindicatedSerious - Use AlternativeSignificant - Monitor CloselyMinorAll Interactions Sort By: SeverityName Contraindicated (0)Serious - Use Alternative (10)aldesleukinbeclomethasone, inhaled decreases effects of aldesleukin by Other (see comment). Avoid or Use Alternate Drug. Comment: Cordicosteroids may interfere with antitumor effects of biological response modulators.BCG intravesical livebeclomethasone, inhaled increases effects of BCG intravesical live by Other (see comment). Avoid or Use Alternate Drug. Comment: May interfere with response to intravesicle TICE BCG response.BCG vaccine livebeclomethasone, inhaled increases effects of BCG vaccine live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. May interfere with generation of an adequate immune response to BCG vaccine.echinaceaechinacea decreases effects of beclomethasone, inhaled by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Monitor for reduced efficacy of immunosuppressant when used concomitantly.hyaluronidasebeclomethasone, inhaled will decrease the level or effect of hyaluronidase by unspecified interaction mechanism. Avoid or Use Alternate Drug. Larger hyaluronidase doses may be required to achieve desired effectleflunomidebeclomethasone, inhaled increases toxicity of leflunomide by unspecified interaction mechanism. Avoid or Use Alternate Drug. May increase risk of hematologic toxicities; should monitor for bone marrow suppression at least monthly throughout duration of concurrent therapy when leflunomide is given with another immunosuppressants.macimorelinbeclomethasone, inhaled, macimorelin. unspecified interaction mechanism. Avoid or Use Alternate Drug. Drugs that directly affect the pituitary secretion of growth hormone (GH) may impact the accuracy of the macimorelin diagnostic test. Allow sufficient washout time of drugs affecting GH growth hormone release before administering prior to administration of macimorelin. Drugs that directly affect the pituitary secretion of growth hormone (GH) may impact the accuracy of the macimorelin diagnostic test. Allow sufficient washout time of drugs affecting GH release before administering macimorelin.natalizumabbeclomethasone, inhaled increases toxicity of natalizumab by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Before initiating natalizumab, taper of steroids patients receiving chronic corticosteroids .pimecrolimusbeclomethasone, inhaled increases toxicity of pimecrolimus by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Effects are dependent on immunosuppression, intensity, and duration.tacrolimus ointmentbeclomethasone, inhaled increases toxicity of tacrolimus ointment by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Effects are dependent on immunosuppression, intensity, and duration.Monitor Closely (14)amphotericin B deoxycholatebeclomethasone, inhaled increases toxicity of amphotericin B deoxycholate by Mechanism: unspecified interaction mechanism. Use Caution/Monitor. Corticosteroids may increase the hypokalemic effect of amphotericin B.bumetanidebeclomethasone, inhaled increases toxicity of bumetanide by increasing elimination. Use Caution/Monitor. Corticosteroids may increase the hypkalemic effects of loop diuretics.chlorothiazidebeclomethasone, inhaled increases toxicity of chlorothiazide by increasing elimination. Use Caution/Monitor. May increase the hypokalemic effects of thiazide diuretics.chlorthalidonebeclomethasone, inhaled increases toxicity of chlorthalidone by increasing elimination. Use Caution/Monitor. May increase the hypokalemic effects of thiazide diuretics.corticorelinbeclomethasone, inhaled decreases effects of corticorelin by unspecified interaction mechanism. Use Caution/Monitor. May blunt plasma ACTH response to corticorelin.deferasiroxbeclomethasone, inhaled increases toxicity of deferasirox by unspecified interaction mechanism. Use Caution/Monitor. Increases risk for GI ulceration/irritation or GI bleeding.denosumabdenosumab increases toxicity of beclomethasone, inhaled by immunosuppressive effects; risk of infection. Use Caution/Monitor.ethacrynic acidbeclomethasone, inhaled increases toxicity of ethacrynic acid by increasing elimination. Use Caution/Monitor. Corticosteroids may increase the hypkalemic effects of loop diuretics.furosemidebeclomethasone, inhaled increases toxicity of furosemide by increasing elimination. Use Caution/Monitor. Corticosteroids may increase the hypkalemic effects of loop diuretics.hydrochlorothiazidebeclomethasone, inhaled increases toxicity of hydrochlorothiazide by increasing elimination. Use Caution/Monitor. May increase the hypokalemic effects of thiazide diuretics.sipuleucel-Tbeclomethasone, inhaled decreases effects of sipuleucel-T by unspecified interaction mechanism. Use Caution/Monitor. Drugs that suppress the immune system may inhibit clinical activity of sipuleucel-T.torsemidebeclomethasone, inhaled increases toxicity of torsemide by increasing elimination. Use Caution/Monitor. Corticosteroids may increase the hypkalemic effects of loop diuretics.trastuzumabtrastuzumab, beclomethasone, inhaled. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. .trastuzumab deruxtecantrastuzumab deruxtecan, beclomethasone, inhaled. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. .trastuzumab deruxtecan increases toxicity of beclomethasone, inhaled by unspecified interaction mechanism. Use Caution/Monitor. May enhance the neutropenic effect of immunosuppressants.Minor (0)aldesleukinSerious - Use Alternative (1)beclomethasone, inhaled decreases effects of aldesleukin by Other (see comment). Avoid or Use Alternate Drug. Comment: Cordicosteroids may interfere with antitumor effects of biological response modulators.amphotericin B deoxycholateMonitor Closely (1)beclomethasone, inhaled increases toxicity of amphotericin B deoxycholate by Mechanism: unspecified interaction mechanism. Use Caution/Monitor. Corticosteroids may increase the hypokalemic effect of amphotericin B.BCG intravesical liveSerious - Use Alternative (1)beclomethasone, inhaled increases effects of BCG intravesical live by Other (see comment). Avoid or Use Alternate Drug. Comment: May interfere with response to intravesicle TICE BCG response.BCG vaccine liveSerious - Use Alternative (1)beclomethasone, inhaled increases effects of BCG vaccine live by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. May interfere with generation of an adequate immune response to BCG vaccine.bumetanideMonitor Closely (1)beclomethasone, inhaled increases toxicity of bumetanide by increasing elimination. Use Caution/Monitor. Corticosteroids may increase the hypkalemic effects of loop diuretics.chlorothiazideMonitor Closely (1)beclomethasone, inhaled increases toxicity of chlorothiazide by increasing elimination. Use Caution/Monitor. May increase the hypokalemic effects of thiazide diuretics.chlorthalidoneMonitor Closely (1)beclomethasone, inhaled increases toxicity of chlorthalidone by increasing elimination. Use Caution/Monitor. May increase the hypokalemic effects of thiazide diuretics.corticorelinMonitor Closely (1)beclomethasone, inhaled decreases effects of corticorelin by unspecified interaction mechanism. Use Caution/Monitor. May blunt plasma ACTH response to corticorelin.deferasiroxMonitor Closely (1)beclomethasone, inhaled increases toxicity of deferasirox by unspecified interaction mechanism. Use Caution/Monitor. Increases risk for GI ulceration/irritation or GI bleeding.denosumabMonitor Closely (1)denosumab increases toxicity of beclomethasone, inhaled by immunosuppressive effects; risk of infection. Use Caution/Monitor.echinaceaSerious - Use Alternative (1)echinacea decreases effects of beclomethasone, inhaled by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Monitor for reduced efficacy of immunosuppressant when used concomitantly.ethacrynic acidMonitor Closely (1)beclomethasone, inhaled increases toxicity of ethacrynic acid by increasing elimination. Use Caution/Monitor. Corticosteroids may increase the hypkalemic effects of loop diuretics.furosemideMonitor Closely (1)beclomethasone, inhaled increases toxicity of furosemide by increasing elimination. Use Caution/Monitor. Corticosteroids may increase the hypkalemic effects of loop diuretics.hyaluronidaseSerious - Use Alternative (1)beclomethasone, inhaled will decrease the level or effect of hyaluronidase by unspecified interaction mechanism. Avoid or Use Alternate Drug. Larger hyaluronidase doses may be required to achieve desired effecthydrochlorothiazideMonitor Closely (1)beclomethasone, inhaled increases toxicity of hydrochlorothiazide by increasing elimination. Use Caution/Monitor. May increase the hypokalemic effects of thiazide diuretics.leflunomideSerious - Use Alternative (1)beclomethasone, inhaled increases toxicity of leflunomide by unspecified interaction mechanism. Avoid or Use Alternate Drug. May increase risk of hematologic toxicities; should monitor for bone marrow suppression at least monthly throughout duration of concurrent therapy when leflunomide is given with another immunosuppressants.macimorelinSerious - Use Alternative (1)beclomethasone, inhaled, macimorelin. unspecified interaction mechanism. Avoid or Use Alternate Drug. Drugs that directly affect the pituitary secretion of growth hormone (GH) may impact the accuracy of the macimorelin diagnostic test. Allow sufficient washout time of drugs affecting GH growth hormone release before administering prior to administration of macimorelin. Drugs that directly affect the pituitary secretion of growth hormone (GH) may impact the accuracy of the macimorelin diagnostic test. Allow sufficient washout time of drugs affecting GH release before administering macimorelin.natalizumabSerious - Use Alternative (1)beclomethasone, inhaled increases toxicity of natalizumab by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Before initiating natalizumab, taper of steroids patients receiving chronic corticosteroids .pimecrolimusSerious - Use Alternative (1)beclomethasone, inhaled increases toxicity of pimecrolimus by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Effects are dependent on immunosuppression, intensity, and duration.sipuleucel-TMonitor Closely (1)beclomethasone, inhaled decreases effects of sipuleucel-T by unspecified interaction mechanism. Use Caution/Monitor. Drugs that suppress the immune system may inhibit clinical activity of sipuleucel-T.tacrolimus ointmentSerious - Use Alternative (1)beclomethasone, inhaled increases toxicity of tacrolimus ointment by immunosuppressive effects; risk of infection. Avoid or Use Alternate Drug. Effects are dependent on immunosuppression, intensity, and duration.torsemideMonitor Closely (1)beclomethasone, inhaled increases toxicity of torsemide by increasing elimination. Use Caution/Monitor. Corticosteroids may increase the hypkalemic effects of loop diuretics.trastuzumabMonitor Closely (1)trastuzumab, beclomethasone, inhaled. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. .trastuzumab deruxtecanMonitor Closely (2)trastuzumab deruxtecan, beclomethasone, inhaled. Either increases toxicity of the other by immunosuppressive effects; risk of infection. Use Caution/Monitor. Neutropenia or febrile neutropenia incidence were increased when trastuzumab was coadministered with myelosuppressive chemotherapy. . trastuzumab deruxtecan increases toxicity of beclomethasone, inhaled by unspecified interaction mechanism. Use Caution/Monitor. May enhance the neutropenic effect of immunosuppressants. >10% ≥ 12 years (MDI) Pharyngitis (5-27%) Headache (8-25%) Upper respiratory tract infection (URI) (5-11%) 1-10% 4-12 years (RediHaler) Vomiting, 80-160 mcg (1.6%) Headache, 80 mcg (1.6%) URI, 80 mcg (2.4%) Cough, 160 mcg (2.4%) Pyrexia, 160 mcg (3.2%) Pharyngitis, 80-160 mcg (3.2%) Nasopharyngitis, 80 mcg (4%) Viral URI, 80-160 mcg (4%) Headache, 160 mcg (4%) Nasopharyngitis, 160 mcg (8.8%) ≥12 years (RediHaler) Increased asthma symptoms (2-4%) URI, 320 mcg (4%) Nasopharyngitis, 80 mcg (4%) Nasopharyngitis, 80 mcg (4%) Viral URI, 80 mcg (3%) Sinusitis, 80 mcg (3%) URI, 640 mcg (3%) Oral candidiasis, 320 mcg (3%) URI, 80-160 mcg (3%) Rhinitis allergic, 160 mcg (3%) Sinusitis (3%) Oral symptoms (2-3%) Nasopharyngitis, 160 mcg (2%) Oropharyngeal pain, 80-160 mcg (2%) Oral candidiasis, 160 mcg (2%) Nasopharyngitis, 320-640 mcg (1%) <1% 4-12 years (RediHaler) Cough, 80 mcg (0.8%) URI, 80 mcg (0.8%) Pyrexia, 80 mcg (0.8%) ≥12 years (RediHaler) Oropharyngeal pain, 320 mcg (<1%) Viral URI, 80 mcg (<1%) Sinusitis, 320-640 mcg (<1%) Rhinitis allergic, 640 mcg (<1%) Postmarketing Reports Psychiatric events and behavioral changes (eg, aggression, depression, sleep disorders, psychomotor hyperactivity, and suicidal ideation [primarily in children]) Blurred vision, central serous chorioretinopathy Immunosuppression and risk of infections Hypercorticism and adrenal suppression Reduction in bone mineral density Glaucoma and cataracts Contraindications Hypersensitivity Primary treatment of status asthmaticus, acute bronchospasm Cautions Immediate hypersensitivity reactions may occur; discontinue beclomethasone inhaler if such reactions occur May decrease growth velocity in children; titrate dose to the lowest effective dose to relieve signs/symptoms Kaposi sarcoma associated with prolonged corticosteroid treatment; if observed, consider discontinuing therapy Psychiatric disturbances reported with corticosteroid use; psychiatric conditions, including depression, euphoria, personality changes, insomnia, and mood swings may be exacerbated by corticosteroid use Following initiation of inhaled corticosteroids, rare cases of vasculitis or eosinophilic conditions may occur after decrease and/or withdrawal of oral corticosteroid therapy Use caution in patients with heart failure (long-term use associated with fluid retention), diabetes mellitus (may lead to hyperglycemia), gastrointestinal disease (diverculitis, peptic ulcer, ulcerative colitis due to perforation risk), myasthenia gravis (exacerbation may occur), myocardial infarct (exacerbation of